

# MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

## Licensee

1. Putnam General Hospital  
1400 Hospital Drive,  
P. O. Box 507

3. License number 47-23070-01

2. Hurricane, West Virginia 25526

4. Expiration date December 31, 1988

5. Docket or Reference No. 030-20237 (47-23012-01)

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35

A. Any radio-pharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35

A. As necessary for uses authorized in Subitem 9.A.

B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35

B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35

B. 2 000 millicuries of each byproduct material authorized in Subitem 6.B.

C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35

C. Any radio-pharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35

C. As necessary for uses authorized in Subitem 9.C.

D. Iodine 131

D. Iodide

D. 30 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

8511180448 B50405  
REG2 LIC30  
47-23070-01 PDR

ML20  
11

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

47-23070-01

Docket or Reference number

030-20237 (47-23012-01)

(Cont'd)

## CONDITIONS

- B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- D. For use in the treatment of Thyroid carcinoma

## CONDITIONS

10. Licensed material will be used only at the licensee's Nuclear Medicine Laboratory, 1200C Hospital Drive, Hurricane, West Virginia.
11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
12. Licensed material listed in Item 9 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

(NAME)

(USES)

Carl B. Binns, M.D.

Groups I, II, and III

Paul Francke, M.D.

Groups I, II, III, and IV

Thomas M. Hayes, M.D.

Groups I, II, and III

Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma

Martin S. Wershba, M.D.

Groups I, II, and III

Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

47-23070-01

Docket or Reference number

030-20237 (47-23012-01)

(Condition 12 Cont'd)

(NAME)

(USES)

Carl R. Duncan, M.D.

Groups I, II, and III  
Iodine 131 as iodide for treatment of  
hyperthyroidism, cardiac dysfunction  
and thyroid carcinoma

Ravindra Gogineni, M.D.

Groups I, II, and III  
Iodine 131 as iodide for thyroid uptake  
studies and for treatment of  
hyperthyroidism, cardiac dysfunction

Alan R. Nicholas, M.D.

Groups I, II, and III

13. The Radiation Protection Officer for the activities authorized by this license is Martin S. Wershba, M.D.
14. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of the Code of Federal Regulations.
15. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
  - B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity can be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
  - C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

47-23070-01

Docket or Reference number

030-20237 (47-23012-01)

(Cont'd)

## CONDITIONS

16. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated November 23, 1983 and letters dated November 28, 1983, July 17, 1984, January 29, 1985, and March 29, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

PAUL R. GUINN

Date APR 05 1985

By

Region II, Nuclear Materials  
Safety Section101 Marietta Street, Suite 2900  
Atlanta, GA 30323